Australia markets closed
  • ALL ORDS

    7,599.90
    -137.00 (-1.77%)
     
  • ASX 200

    7,279.30
    -128.00 (-1.73%)
     
  • AUD/USD

    0.7128
    -0.0061 (-0.86%)
     
  • OIL

    68.15
    -10.24 (-13.06%)
     
  • GOLD

    1,785.50
    +1.20 (+0.07%)
     
  • BTC-AUD

    75,991.08
    -7,638.31 (-9.13%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • AUD/EUR

    0.6294
    -0.0117 (-1.82%)
     
  • AUD/NZD

    1.0443
    -0.0039 (-0.37%)
     
  • NZX 50

    12,628.89
    -165.72 (-1.30%)
     
  • NASDAQ

    16,025.58
    -342.23 (-2.09%)
     
  • FTSE

    7,044.03
    -266.34 (-3.64%)
     
  • Dow Jones

    34,899.34
    -905.04 (-2.53%)
     
  • DAX

    15,257.04
    -660.94 (-4.15%)
     
  • Hang Seng

    24,080.52
    -659.64 (-2.67%)
     
  • NIKKEI 225

    28,751.62
    -747.66 (-2.53%)
     

DelveInsight Analyzes a Thriving Cutaneous Lupus Erythematosus Pipeline in the Coming Years as Key Pharma Companies Enter the Sphere

·7-min read

The Cutaneous Lupus Erythematosus Pipeline is flourishing with novel treatment agents targeted to meet the unmet need in the Cutaneous Lupus Erythematosus treatment domain.

Las Vegas, USA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- DelveInsight Analyzes a Thriving Cutaneous Lupus Erythematosus Pipeline in the Coming Years as Key Pharma Companies Enter the Sphere

The Cutaneous Lupus Erythematosus Pipeline is flourishing with novel treatment agents targeted to meet the unmet need in the Cutaneous Lupus Erythematosus treatment domain.

DelveInsight’s Cutaneous Lupus Erythematosus Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain.

Some of the salient features from the Cutaneous Lupus Erythematosus Pipeline report:

  • DelveInsight’s Cutaneous Lupus Erythematosus Pipeline analysis depicts the space with 10+ active players working to develop 10+ pipeline therapies.

  • Major pharmaceutical companies are developing potential drug candidates to improve the Cutaneous Lupus Erythematosus treatment scenario, such as Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, AstraZeneca, and others.

  • Key Cutaneous Lupus Erythematosus pipeline therapies such as HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others are under investigation in different phases of clinical trials.

  • In June 2021, Denali Therapeutics announced that its partner Sanofi had commenced dosing in a Phase II study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with Cutaneous Lupus Erythematosus (CLE).

Request for Sample to know which pharma company is anticipated to take charge of Cutaneous Lupus Erythematosus pipeline in the forthcoming years @ Cutaneous Lupus Erythematosus Forecast

The Cutaneous Lupus Erythematosus pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Cutaneous Lupus Erythematosus products, comprehensive assessment of driving and restraining factors, along with the opportunities and risks in the Cutaneous Lupus Erythematosus pipeline landscape.

Cutaneous Lupus Erythematosus Overview

Cutaneous Lupus Erythematosus is an autoimmune disease that can present as isolated skin disease or as a manifestation within the spectrum of systemic lupus erythematosus. Cutaneous Lupus Erythematosus can occur as a manifestation of systemic lupus erythematosus (SLE) or independent of SLE.

The clinical spectrum of Cutaneous Lupus Erythematosus is broad, ranging from isolated discoid plaques to widespread skin lesions. Acute Cutaneous Lupus Erythematosus typically presents as transient erythematous patches associated with a flare of systemic lupus erythematosus.

Discover more about the disease, treatments, and pipeline therapies @ Cutaneous Lupus Erythematosus Pipeline Assessment

Cutaneous Lupus Erythematosus Pipeline Drugs

Drug

Company

Phase

MoA

RoA

HT-005

Hoth Therapeutics

Preclinical

Cannabinoid receptor CB1, CB2 agonists

Topical

CBS004

Centessa Pharmaceuticals

Preclinical

CLEC4C protein inhibitors

Parenteral

BMS-986256

Bristol-Myers Squibb

Phase I

Toll-like receptor 7,8 antagonists

NA

M5049

Merck

Phase I

Toll-like receptor 7,8 antagonists

Oral

BMS-986165

Bristol-Myers Squibb

Phase II

TYK2 kinase inhibitors

NA

BIIB059

Biogen

Phase II

CLEC4C protein inhibitors

Subcutaneous

SAR443122

Sanofi

Phase II

RIPK1 protein inhibitors

Oral

Request for Sample to get an overview of the pipeline landscape @ Cutaneous Lupus Erythematosus Pipeline Analysis

Cutaneous Lupus Erythematosus Therapeutics Assessment

The Cutaneous Lupus Erythematosus Pipeline report proffers an integral view of the Cutaneous Lupus Erythematosus emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.

By Product Type

  • Mono

  • Combination

  • Mono/Combination

By Stage

  • Discovery

  • Pre-clinical

  • Phase I

  • Phase II

  • Phase III

  • Pre-registration

By Route of Administration

  • Subcutaneous

  • Intravenous

  • Oral

  • Parenteral

  • Topical

By Molecule Type

  • Cannabinoids

  • Monoclonal antibodies

  • Arachidonic acids

  • Small molecules

By Mechanism of Action

  • Cannabinoid receptor CB1, CB2 agonists

  • CLEC4C protein inhibitors

  • Toll-like receptor 7,8 antagonists

  • TYK2 kinase inhibitors

  • RIPK1 protein inhibitors

Scope of the Cutaneous Lupus Erythematosus Pipeline Report

  • Coverage: Global

  • Major Players: Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, AstraZeneca, and others

  • Key Cutaneous Lupus Erythematosus Pipeline Therapies: HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others

For rich insights into emerging therapies and assessment, visit @ Cutaneous Lupus Erythematosus Emerging Novel Therapies

Table of Contents

1

Introduction

2

Executive Summary

3

Cutaneous Lupus Erythematosus: Overview

4

Pipeline Therapeutics

5

Cutaneous Lupus Erythematosus: Late Stage Products (Pre-registration)

6

Cutaneous Lupus Erythematosus: Late Stage Products (Phase III)

7

Cutaneous Lupus Erythematosus: Mid Stage Products (Phase II)

8

Cutaneous Lupus Erythematosus: Early Stage Products (Phase I)

9

Pre-clinical and Discovery Stage Products

10

Therapeutic Assessment Cutaneous Lupus Erythematosus

11

Inactive Products Cutaneous Lupus Erythematosus

12

Cutaneous Lupus Erythematosus - Unmet Needs

13

Cutaneous Lupus Erythematosus - Market Drivers and Barriers

14

Appendix

15

About DelveInsight

Get a customized pipeline report @ Cutaneous Lupus Erythematosus Ongoing Clinical Trials

Track and assess a candidate’s clinical development journey through Comparative Therapeutic Assessment

Related Reports

Cutaneous Lupus Erythematosus Market

DelveInsight's "Cutaneous Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, and others.

Systemic Lupus Erythematosus Market

DelveInsight’s ‘Systemic Lupus Erythematosus - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies involved like GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer and many others.

Psoriatic Arthritis Market

DelveInsight’s ‘Psoriatic Arthritis (PsA)– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the historical and forecasted epidemiology profiling of pipeline therapeutics, ongoing clinical trials, key cross competition, and key pharmaceuticals involved like AbbVie, Amgen/Pfizer, Bristol-Myers Squibb, Janssen Biotech, Amgen, Eli Lilly and Company, Pfizer, UCB, Bristol-Myers Squibb, Sun Pharma Global FZE, and many others.

RIPK1 inhibitor Pipeline

DelveInsight’s, “RIPK1 inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in RIPK1 inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment, and key companies involved such as Denali Therapeutics, Sanofi, Voronoi, GenFleet Therapeutics, GlaxoSmithKline, and several others.

TYK2 Kinase Inhibitors Pipeline

DelveInsight’s, “TYK2 Kinase Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, pipeline products in this space and key companies involved such as Incyte Corporation, Bristol-Myers Squibb, Oncostellae, Pfizer, Galapagos, Haisco Pharmaceutical Group, Sareum, Oncostellae, and several others.

Friedreich's Ataxia Market

DelveInsight's "Friedreich's Ataxia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Friedreich's Ataxia, historical and forecasted epidemiology as well as market share of the individual therapies, current and forecasted Friedreich's Ataxia market Size treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Cutaneous Lupus Erythematosus Epidemiology

DelveInsight's 'Cutaneous Lupus Erythematosus (CLE) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Cutaneous Lupus Erythematosus (CLE) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Browse Through Our Blog Posts

Systemic Lupus Erythematosus Market: How the Leading Companies are Countering the Rising Prevalence?
Systemic Lupus Erythematosus is a chronic inflammatory disease that affects connective tissues such as cartilage and blood vessel lining, which provide strength and flexibility to body structures.

Aurinia’s Lupkynis for Lupus
Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis.

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies
As per the American Autoimmune Related Diseases Association (AARDA), nearly 50 million people in the USA are affected by autoimmune diseases such as rheumatoid arthritis, psoriasis, and lupus.

Pipeline Assessment revolving around client’s area of interest supporting strategic decisions

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting